These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23015264)

  • 1. Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model.
    Lewis AL; Holden RR; Chung ST; Czuczman P; Kuchel T; Finnie J; Porter S; Foster D
    J Mater Sci Mater Med; 2013 Jan; 24(1):115-27. PubMed ID: 23015264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
    Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
    J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model.
    Rao PP; Pascale F; Seck A; Auperin A; Drouard-Troalen L; Deschamps F; Teriitheau C; Paci A; Denys A; Bize P; de Baere T
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1448-59. PubMed ID: 22358992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy compared between irinotecan-loaded microspheres HepaSphere and DC bead in a model of VX2 liver metastases in the rabbit.
    Namur J; Pascale F; Maeda N; Sterba M; Ghegediban SH; Verret V; Paci A; Seck A; Osuga K; Wassef M; Reb P; Laurent A
    J Vasc Interv Radiol; 2015 Jul; 26(7):1067-1075.e3. PubMed ID: 25952641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
    Bhutiani N; Akinwande O; Martin RC
    World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the plasmatic and parenchymal elution kinetics of two different irinotecan-loaded drug-eluting embolics in a pig model.
    Gnutzmann DM; Mechel J; Schmitz A; Köhler K; Krone D; Bellemann N; Gockner TL; Mokry T; Kortes N; Sommer CM; Kauczor HU; Radeleff BA; Stampfl U
    J Vasc Interv Radiol; 2015 May; 26(5):746-54. PubMed ID: 25704223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Akinwande O; Scoggins C; Martin RC
    Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series.
    Jones RP; Dunne D; Sutton P; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Koelblinger C; Stättner S; Stremitzer S; Gruenberger T; Poston GJ
    HPB (Oxford); 2013 Jan; 15(1):71-7. PubMed ID: 23216781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.
    Taylor RR; Tang Y; Gonzalez MV; Stratford PW; Lewis AL
    Eur J Pharm Sci; 2007 Jan; 30(1):7-14. PubMed ID: 17030118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.
    Fiorentini G; Aliberti C; Tilli M; Mulazzani L; Graziano F; Giordani P; Mambrini A; Montagnani F; Alessandroni P; Catalano V; Coschiera P
    Anticancer Res; 2012 Apr; 32(4):1387-95. PubMed ID: 22493375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
    Venturini M; Sallemi C; Agostini G; Marra P; Cereda S; Reni M; Aldrighetti L; De Cobelli F; Del Maschio A
    Br J Radiol; 2016 Nov; 89(1067):20160247. PubMed ID: 27558984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study.
    Iezzi R; Marsico VA; Guerra A; Cerchiaro E; Cassano A; Basso M; Devicienti E; Rodolfino E; Barone C; Bonomo L
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1523-31. PubMed ID: 25799948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.
    Martin RC; Joshi J; Robbins K; Tomalty D; Bosnjakovik P; Derner M; Padr R; Rocek M; Scupchenko A; Tatum C
    Ann Surg Oncol; 2011 Jan; 18(1):192-8. PubMed ID: 20740319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.
    Forster RE; Small SA; Tang Y; Heaysman CL; Lloyd AW; Macfarlane W; Phillips GJ; Antonijevic MD; Lewis AL
    J Mater Sci Mater Med; 2010 Sep; 21(9):2683-90. PubMed ID: 20563626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
    Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
    Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases.
    Tang Y; Taylor RR; Gonzalez MV; Lewis AL; Stratford PW
    J Control Release; 2006 Nov; 116(2):e55-6. PubMed ID: 17718969
    [No Abstract]   [Full Text] [Related]  

  • 19. Bradycardia associated with drug-eluting beads loaded with irinotecan (DEBIRI) infusion for colorectal liver metastases.
    Pua U
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):864-6. PubMed ID: 22722719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
    Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.